Smith & Nephew (LON:SN - Get Free Report) had its target price lowered by equities researchers at Berenberg Bank from GBX 1,300 to GBX 1,250 in a report issued on Friday,London Stock Exchange reports. The firm presently has a "hold" rating on the stock. Berenberg Bank's price target would suggest a potential upside of 13.07% from the company's current price.
SN has been the topic of several other reports. Shore Capital Group reiterated a "buy" rating and issued a GBX 1,000 price target on shares of Smith & Nephew in a research report on Tuesday, July 21st. UBS Group reaffirmed a "neutral" rating and issued a GBX 1,300 target price on shares of Smith & Nephew in a research note on Tuesday, May 5th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and set a GBX 1,400 target price on shares of Smith & Nephew in a report on Thursday, July 30th. Royal Bank Of Canada dropped their price target on Smith & Nephew from GBX 1,350 to GBX 1,250 and set a "sector perform" rating for the company in a research report on Thursday, August 6th. Finally, JPMorgan Chase & Co. cut their price target on Smith & Nephew from GBX 1,438 to GBX 1,290 and set a "neutral" rating for the company in a report on Thursday, August 6th. Three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Smith & Nephew presently has a consensus rating of "Hold" and a consensus price target of GBX 1,310.
Get Our Latest Stock Report on Smith & Nephew
Smith & Nephew Trading Up 1.1%
LON:SN opened at GBX 1,105.50 on Friday. The company has a debt-to-equity ratio of 73.07, a current ratio of 2.14 and a quick ratio of 0.84. The stock has a market cap of £12.12 billion, a P/E ratio of 39.80, a P/E/G ratio of 0.46 and a beta of 0.69. The company's fifty day simple moving average is GBX 1,135.64 and its 200-day simple moving average is GBX 1,189.09.
Smith & Nephew Company Profile
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.